Martina Widman - Diamyd Medical Chief Officer
| DMN Stock | EUR 0.99 0.04 4.21% |
Insider
Martina Widman is Chief Officer of Diamyd Medical AB
| Age | 42 |
| Phone | 46 86 61 00 26 |
| Web | https://www.diamyd.com |
Diamyd Medical Management Efficiency
The company has return on total asset (ROA) of (0.2531) % which means that it has lost $0.2531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4155) %, meaning that it generated substantial loss on money invested by shareholders. Diamyd Medical's management efficiency ratios could be used to measure how well Diamyd Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
| Torsten Leue | Talanx AG | 57 | |
| Christopher Lohmann | Talanx AG | 55 | |
| Edgar Puls | Talanx AG | 50 | |
| Rick Carron | Superior Plus Corp | N/A | |
| Ash Rajendra | Superior Plus Corp | N/A | |
| Fei Wang | Origin Agritech | 40 | |
| Patric Erlandsson | SIVERS SEMICONDUCTORS AB | 51 | |
| Justin Scarpulla | Identiv | 50 | |
| Min Tang | Origin Agritech | 61 | |
| Larry Cordell | Origin Agritech | 56 | |
| Steven Humphreys | Identiv | 62 | |
| Caroline Schlienkamp | Talanx AG | 49 | |
| David Bullock | Origin Agritech | 49 | |
| Gengchen Han | Origin Agritech | 58 | |
| MBA MBA | Superior Plus Corp | 70 | |
| Yasheng Yang | Origin Agritech | 51 | |
| Ravi Mallela | NMI Holdings | 53 | |
| Leigh Dow | Identiv | N/A | |
| CCLP CMA | Superior Plus Corp | 62 | |
| Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
Management Performance
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 |
Diamyd Medical AB Leadership Team
Elected by the shareholders, the Diamyd Medical's board of directors comprises two types of representatives: Diamyd Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diamyd. The board's role is to monitor Diamyd Medical's management team and ensure that shareholders' interests are well served. Diamyd Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diamyd Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ulf MBA, CEO Pres | ||
| Anton Lindqvist, Chief Officer | ||
| Martina Widman, Chief Officer | ||
| Anna BSc, Chief Officer | ||
| Christoph Nowak, Chief Officer | ||
| Eva Karlstrom, Chief Officer |
Diamyd Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Diamyd Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.42 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 96.81 M | |||
| Shares Outstanding | 76.93 M | |||
| Shares Owned By Insiders | 35.22 % | |||
| Shares Owned By Institutions | 0.26 % | |||
| Price To Book | 5.52 X | |||
| Price To Sales | 2,594 X | |||
| Revenue | 454 K | |||
| Gross Profit | (3.95 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Diamyd Stock
Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.